- Home
- / Purple Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Purple Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.5
2024-10-29
Market Capitalization
$6.6 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0M | 1.0M | 1.0M | |||||
| Gross profit | 2.6M | 1.6M | 1.2M | 66.0K | ||||
| Gross profit margin, % | 159.6% | 118.2% | ||||||
| Operating expense total | 10.5M | 8.6M | 13.8M | 17.9M | 22.6M | 22.1M | 10.6M | 6.8M |
| Depreciation and amortization | 7.0K | 178.0K | 2.0K | 60.0K | 49.0K | 197.0K | 186.0K | 20.7M |
| EBITDA | (7.8M) | (7.0M) | (12.6M) | (17.9M) | (22.6M) | (22.1M) | (10.6M) | (6.8M) |
| EBITDA margin, % | -697.8% | -1261.0% | ||||||
| EBIT | (8.3M) | (7.2M) | (12.6M) | (17.9M) | (22.6M) | (22.3M) | (10.8M) | (27.5M) |
| EBIT margin, % | -715.6% | -1261.2% | ||||||
| Interest income | 93.0K | 151.0K | 254.0K | 320.0K | 532.0K | 474.0K | 260.0K | 227.0K |
| Interest expense | 2.1M | 431.0K | 943.0K | |||||
| Pre tax profit | (5.6M) | (5.7M) | (28.1M) | (17.8M) | (21.8M) | (20.0M) | (7.3M) | (26.5M) |
| Income tax expense | 216.0K | |||||||
| Net Income | (5.6M) | (5.9M) | (28.1M) | (17.8M) | (21.8M) | (20.0M) | (7.3M) | (26.5M) |